These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 37298274)

  • 21. Pharmacotherapy in type 2 diabetes: a functional schema for drug classification.
    McGill JB
    Curr Diabetes Rev; 2012 Jul; 8(4):257-67. PubMed ID: 22515702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium alginate-based drug delivery for diabetes management: A review.
    Shaikh MAJ; Gupta G; Afzal O; Gupta MM; Goyal A; Altamimi ASA; Alzarea SI; Almalki WH; Kazmi I; Negi P; Singh SK; Dua K
    Int J Biol Macromol; 2023 May; 236():123986. PubMed ID: 36906199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients.
    Anderson S; Cotiguala L; Tischer S; Park JM; McMurry K
    Ann Pharmacother; 2021 Apr; 55(4):496-508. PubMed ID: 32795145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of type 2 diabetes: new and future developments in treatment.
    Tahrani AA; Bailey CJ; Del Prato S; Barnett AH
    Lancet; 2011 Jul; 378(9786):182-97. PubMed ID: 21705062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetics of Type 2 Diabetes-Progress and Prospects.
    Nasykhova YA; Tonyan ZN; Mikhailova AA; Danilova MM; Glotov AS
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.
    Tong L; Adler S
    Postgrad Med; 2018 May; 130(4):381-393. PubMed ID: 29667921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacotherapy of hyperglycemia.
    Kulasa KM; Henry RR
    Expert Opin Pharmacother; 2009 Oct; 10(15):2415-32. PubMed ID: 19743938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.
    Yassin SA; Aroda VR
    Drug Des Devel Ther; 2017; 11():923-937. PubMed ID: 28356718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
    Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.
    Abbatecola AM; Maggi S; Paolisso G
    Drugs Aging; 2008; 25(11):913-25. PubMed ID: 18947259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type 2 Diabetes Medication and Cardiovascular Benefits.
    Shrestha A; Munankarmi R
    S D Med; 2021 Mar; 74(3):132-135. PubMed ID: 34232594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
    Schwartz SS; Ahmed I
    Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes.
    Chang HY; Singh S; Mansour O; Baksh S; Alexander GC
    JAMA Intern Med; 2018 Sep; 178(9):1190-1198. PubMed ID: 30105373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes.
    Aronoff SL
    Postgrad Med; 2017 Mar; 129(2):231-241. PubMed ID: 28118069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus.
    Moore KB; Saudek CD
    Am J Ther; 2008; 15(5):484-91. PubMed ID: 18806525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
    Ovalle F
    Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding the impact of commonly utilized, non-insulin, glucose-lowering drugs on body weight in patients with type 2 diabetes.
    Hurren KM; Dunham MW
    Expert Opin Pharmacother; 2018 Jul; 19(10):1087-1095. PubMed ID: 29958007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
    Russell S
    Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Glucose-Lowering Agents for Diabetic Kidney Disease.
    de Vos LC; Hettige TS; Cooper ME
    Adv Chronic Kidney Dis; 2018 Mar; 25(2):149-157. PubMed ID: 29580579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.